Sign in to view content

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial

Diana V Do, MD, FASRS

Video
Published 2024

Related

Association Between DRSS Changes and Visual/ Anatomic Outcomes in Patients With Moderately Severe to Severe NPDR: Post Hoc Analysis of PANORAMA
Diana V Do, MD, FASRS
Annual Meeting Talks
2022
Outcomes of Intravitreal Antivascular Endothelial Growth Factor (VEGF) Therapy for Diabetic Macular Edema in Routine Clinical Practice
John D Pitcher, MD
Annual Meeting Talks
2018
Treat-and-Extend Versus Bimonthly Dosing With Aflibercept for the Treatment of Diabetic Macular Edema, 1-Year Outcomes (EVADE Study)
Dilsher S. Dhoot, MD
Annual Meeting Talks
2018

Category: Retinal Vascular Disease

See more